Diltiazem in Jervell and Lange-Nielsen Syndrome

Phase 4

Completed

• Conditions: Jervell and Lange Nielsen Syndrome
• Interventions: Drug: diltiazem

• Registration Number: NCT06534671
• Lead Sponsor: Vanderbilt University Medical Center

Brief Summary

This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (within minutes) will be observed.

Detailed Description

Subjects will be recruited by study personnel and will be scheduled for a single outpatient visit. If an implanted cardiac device (pacemaker or ICD) is in place, it will be interrogated to ensure no recent rhythm abnormalities. Just prior to administering diltiazem, an ECG and BP will be obtained. If baseline SBP is \< 100 mm Hg or DBP \< 60 mm Hg, the study will be terminated. A single dose of I.V. diltiazem (0.25 mg/kg over 2 minutes) will be administered with 12-lead ECG and BP obtained at 2, 5, 7, 10, 15 and 20 minutes. If at 10 minutes there has been no QT shortening, and the SBP is stable (\<20% drop from baseline and \> 100 mm Hg) a repeat dose (0.35 mg/kg) will be given at 15 minutes, with 12-lead ECG and BP obtained at 17, 20, 22, 25, 30 and 35 minutes. After 20 minutes (single dose) or 35 minutes (2 doses), the test will end and the subject will remain on continuous telemetry for 2 hours. Prior to discharge the IV will be removed. The primary analysis will be a repeated measures (paired) comparison of the QTc at baseline and following diltiazem.

Study Timeline

• Study First Submitted: 2024-07-29
• Study First Submitted QC: 2024-07-29
• Study First Posted: 2024-08-02
• Study Start: 2024-10-16
• Primary Completion: 2024-10-23
• Study Completion: 2024-10-23
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-13
• Last Update Posted: 2024-12-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• Age greater than 18 years
• Genetically confirmed diagnosis of Jervell and Lange-Nielsen syndrome
• Able to provide written informed consent

Exclusion Criteria

• Known hypersensitivity to diltiazem
• Pregnancy
• Congestive heart failure, angina, preexcitation, or chronic obstructive pulmonary disease
• Sick sinus syndrome or atrioventricular block in the absence of a pacemaker/defibrillator
• Any clinically significant ongoing medical or surgical condition that might jeopardize the subject's safety or interfere with the conduct of the study in the judgement of the investigator
• Baseline systolic blood pressure less than 100 Hg or diastolic blood pressure less than 60 Hg

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Diltiazem	diltiazem	IV diltiazem (0.25 mg/kg) will be given over 2 minutes. A second IV dose (0.35 mg/kg) may be given at 10 minutes.

Primary Outcome Measures

Name	Time	Method
QT interval	Baseline	QT interval (on 12-lead ECG) in ms

Trial Locations

Locations (1)

Vanderbilt University Medical Center; 🇺🇸 Nashville, Tennessee, United States